Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice.

Abstract

γ-Aminobutyric acid B (GABAB) receptor activation is a potential therapeutic approach for the treatment of drug addiction, pain, anxiety, and depression. However, full agonists of this receptor induce side-effects, such as sedation, muscle relaxation, tolerance, and cognitive disruption. Positive allosteric modulators (PAMs) of the GABAB receptor may have similar therapeutic effects as agonists with superior side-effect profiles. The present study behaviorally characterized N-([1R,2R,4S]-bicyclo[2.2.1]hept-2-yl)-2-methyl-5-(4-[trifluoromethyl]phenyl)-4-pyrimidinamine (BHF177), a GABAB receptor PAM, in mouse models of anxiety-like behavior, learning and memory. In addition, the effects of BHF177 were compared with the agonist baclofen. Unlike the anxiolytic chlordiazepoxide, baclofen (0.5, 1.5, and 2.5 mg/kg, intraperitoneally) and BHF177 (10, 20, and 40 mg/kg, orally) had no effect on anxiety-like behavior in the elevated plus maze, light/dark box, or Vogel conflict test. Baclofen increased punished drinking in the Vogel conflict test, but this effect may be attributable to the analgesic actions of baclofen. At the highest dose tested (2.5 mg/kg), baclofen-treated mice exhibited sedation-like effects (i.e., reduced locomotor activity) across many of the tests, whereas BHF177-treated mice exhibited no sedation-like effects. BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific. At doses that were not sedative or pro-convulsant, baclofen and BHF177 had no selective effects on fear memory retrieval in contextual and cued fear conditioning or spatial learning and memory in the Barnes maze. These data suggest that BHF177 has little sedative activity, no anxiolytic-like profile, and minimal impairment of learning and memory in mice.

• Authors: Xia Li, Victoria B Risbrough, Chelsea Cates-Gatto, Katarzyna Kaczanowska, M G Finn, Amanda J Roberts, Athina Markou
• Journal: Neuropharmacology (Neuropharmacology) Vol. 70 Pg. 156-67 (Jul 2013) ISSN: 1873-7064 [Electronic] England
• PMID: 23376712 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• GABA-B Receptor Agonists
• N-(bicyclo(2.2.1)hept-2-yl)-2-methyl-5-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine
• Norbornanes
• Pyrimidines
• Chlordiazepoxide
• Baclofen
• Pentylenetetrazole

Topics

• Animals
• Anxiety (drug therapy)
• Baclofen (pharmacology)
• Chlordiazepoxide (pharmacology)
• Dose-Response Relationship, Drug
• GABA-B Receptor Agonists (pharmacology)
• Male
• Maze Learning (drug effects)
• Memory (drug effects)
• Mice
• Motor Activity (drug effects)
• Norbornanes (chemical synthesis, pharmacology)
• Pentylenetetrazole
• Pyrimidines (chemical synthesis, pharmacology)
• Rats
• Seizures (chemically induced, drug therapy)